[Bispecific antibodies in onco-hematology: Applications and perspectives].

Abstract

Bispecific antibodies are novel approaches of immunotherapy engaging immune cells to destroy tumor cells. Their structure is variable and underlies their pharmacocinetic properties. These coumpounds are now being evaluated across multiple hematological malignancies. The anti-CD3/CD19 antibody blinatumomab is the first in class and have been approved for the treatment of patients with Ph-negative B-cell acute lymphoblastic leukemia. Other emerging applications are lymphoma, multiple myeloma and acute myeloid leukemia. The safety profile of bispecific antibodies is acceptable while limited by neurotoxicity and cytokine-release syndrome. The present review aims to depict the landscape of emerging bispecific antibodies currently in development for hematological malignancies.

• Authors: Sabrina Barrière, Nathan El-Ghazzi, Manon Garcia, Romain Guièze
• Journal: Bulletin du cancer (Bull Cancer) Vol. 108 Issue 10S Pg. S195-S204 (Oct 2021) ISSN: 1769-6917 [Electronic] France
• Vernacular Title: Anticorps bispecifiques en oncohématologie : applications et perspectives.
• PMID: 34920803 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2021 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.

Chemical References

• Antibodies, Bispecific
• Antineoplastic Agents, Immunological
• blinatumomab

Topics

• Antibodies, Bispecific (adverse effects, immunology, therapeutic use)
• Antineoplastic Agents, Immunological (therapeutic use)
• Cytokine Release Syndrome (etiology)
• Drug Resistance, Neoplasm (immunology)
• Hematologic Neoplasms (immunology, therapy)
• Humans
• Immunotherapy (methods)
• Leukemia, Myeloid, Acute (immunology, therapy)
• Lymphoma (immunology, therapy)
• Multiple Myeloma (immunology, therapy)
• Neoplasms (immunology, therapy)
• Precursor Cell Lymphoblastic Leukemia-Lymphoma (immunology, therapy)